Twist Bioscience IPO
Twist Bioscience is a synthetic biology company that manufactures synthetic DNA using its proprietary silicon platform. The company's technology enables the production of high-quality synthetic DNA at scale for applications in healthcare, agriculture, chemicals, and data storage. Twist's synthetic DNA is used by researchers, biotechnology companies, and pharmaceutical companies for various applications including drug discovery and development.
What We Know
Twist Bioscience went public in October 2018, trading on NASDAQ under the ticker symbol TWST. The company's IPO raised approximately $70 million at $14 per share. Since going public, Twist has expanded its synthetic biology platform and grown its customer base across multiple industries including pharmaceuticals, agriculture, and industrial chemicals. As a public company, Twist has continued to invest in R&D and expand its manufacturing capabilities while working toward profitability. The company has benefited from growing interest in synthetic biology and has formed partnerships with major pharmaceutical and biotechnology companies to support drug discovery and development programs.
Frequently Asked Questions
Has Twist Bioscience had an IPO?
Yes, Twist Bioscience has been a public company since October 2018. The company went public on NASDAQ under the ticker symbol TWST.
When is the Twist Bioscience IPO date?
Twist Bioscience completed its IPO in October 2018, raising approximately $70 million at $14 per share. The company has been publicly traded for several years.
How can I buy Twist Bioscience stock?
You can buy Twist Bioscience stock through any brokerage account as it trades publicly on NASDAQ under the ticker symbol TWST. The stock is available through online brokers and traditional brokerage services.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts